Table 1.

Patient tumor and clinicopathologic characteristics

MMRBRAFKRASTumor site
dMMR
(N = 329)
pMMR
(N = 2,575)
PMutated
(N = 346)
Nonmutated
(N = 2,485)
PMutated
(N = 1,042)
Nonmutated
(N = 1,863)
PProximal
(N = 1,511)
Distal
(N = 1,463)
P
Age0.001a<0.001a0.706a<0.001a
 Median61.058.065.057.058.058.060.056.0
 Range(22.0–86.0)(19.0–85.0)(31.0–86.0)(19.0–85.0)(22.0–85.0)(19.0–86.0)(19.0–86.0)(19.0–85.0)
Treatment0.004b<0.001b<0.001b0.044b
 mFOLFOX6158 (48%)1,453 (56%)155 (45%)1,409 (57%)700 (67%)909 (49%)808 (53%)836 (57%)
 mFOLFOX6+cetuximab171 (52%)1,122 (44%)191 (55%)1,076 (43%)342 (33%)954 (51%)703 (47%)627 (43%)
Sex<0.001b<0.001b0.311b0.015b
 Female189 (57%)1,189 (46%)224 (65%)1,119 (45%)507 (49%)870 (47%)754 (50%)665 (45%)
 Male140 (43%)1,386 (54%)122 (35%)1,366 (55%)535 (51%)993 (53%)757 (50%)798 (55%)
Histologic grade<0.001b<0.001b<0.001b<0.001b
 High172 (52%)546 (21%)167 (48%)543 (22%)212 (20%)508 (27%)482 (32%)253 (17%)
 Low157 (48%)2,029 (79%)179 (52%)1,942 (78%)830 (80%)1,355 (73%)1,029 (68%)1,210 (83%)
Lymph node involvement0.529b<0.00120.011b0.265b
 1–3198 (60%)1,503 (58%)170 (49%)1,486 (60%)642 (62%)1058 (57%)866 (57%)868 (59%)
 ≥ 4131 (40%)1,072 (42%)176 (51%)999 (40%)400 (38%)805 (43%)645 (43%)595 (41%)
Stage0.012b0.007b0.079b<0.001b
 Missing01011001
 T1 or T232 (10%)410 (16%)37 (11%)389 (16%)159 (15%)278 (15%)185 (12%)272 (19%)
 T3252 (77%)1,855 (72%)253 (73%)1,803 (73%)736 (71%)1,375 (74%)1,119 (74%)1,033 (71%)
 T445 (14%)309 (12%)56 (16%)292 (12%)146 (14%)210 (11%)207 (14%)157 (11%)
Tumor subsite<0.001b<0.001b<0.001b
 Missing3013424139551099926
 Cecum90 (30%)474 (19%)91 (28%)461 (20%)277 (28%)289 (16%)587 (42%)0 (0%)
 Ascending colon88 (29%)362 (15%)91 (28%)337 (14%)177 (18%)271 (15%)471 (33%)0 (0%)
 Hepatic flexure43 (14%)79 (3%)39 (12%)83 (4%)35 (4%)89 (5%)127 (9%)0 (0%)
 Transverse colon41 (14%)178 (7%)49 (15%)168 (7%)82 (8%)137 (8%)227 (16%)0 (0%)
 Splenic flexure8 (3%)102 (4%)7 (2%)99 (4%)49 (5%)61 (3%)0 (0%)116 (8%)
 Descending colon6 (2%)144 (6%)9 (3%)136 (6%)54 (5%)96 (5%)0 (0%)156 (11%)
 Sigmoid colon23 (8%)1,102 (45%)36 (11%)1,062 (45%)313 (32%)811 (46%)0 (0%)1165 (81%)
Tumor site<0.001b<0.001b<0.001b
 Missing8345381925
 Proximal283 (88%)1,168 (46%)287 (84%)1,126 (46%)599 (59%)852 (46%)
 Distal38 (12%)1,373 (54%)54 (16%)1,321 (54%)424 (41%)986 (54%)
KRAS<0.001b<0.001b<0.001b
 Missing540266053
 Mutated49 (15%)981 (39%)0 (0%)1,000 (40%)599 (41%)424 (30%)
 Non-mutated275 (85%)1,554 (61%)344 (100%)1,479 (60%)852 (59%)986 (70%)
KRAS submutation<0.001b<0.001b
 Missing54026006053
 Non-mutated275 (85%)1,554 (61%)344 (100%)1,479 (60%)0 (0%)1,863 (100%)852 (59%)986 (70%)
 Codon 12 Mutant28 (9%)773 (31%)0 (0%)780 (31%)811 (78%)0 (0%)458 (32%)338 (24%)
 Codon 13 Mutant21 (6%)207 (8%)0 (0%)220 (9%)231 (22%)0 (0%)141 (10%)86 (6%)
BRAF<0.001b<0.001b<0.001b
 Missing1110442409888
 Mutated149 (47%)190 (8%)0 (0%)344 (19%)287 (20%)54 (4%)
 Non-mutated169 (53%)2,281 (92%)1,000 (100%)1,479 (81%)1,126 (80%)1,321 (96%)
MMR<0.001b<0.001b<0.001b
 Missing73512346052
 Proficient (p) MMR190 (56%)2,281 (93%)981 (95%)1,554 (85%)1,168 (80%)1,373 (97%)
 Deficient (d) MMR149 (44%)169 (7%)49 (5%)275 (15%)283 (20%)38 (3%)